A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms SELECT Axis 1
- Sponsors AbbVie
- 06 Nov 2018 Planned End Date changed from 27 Dec 2020 to 11 Nov 2020.
- 06 Nov 2018 Planned primary completion date changed from 15 Mar 2019 to 11 Nov 2020.
- 06 Nov 2018 Status changed from recruiting to active, no longer recruiting.